5PSQ-068 Prescription profile of lapatinib in her2-positive breast cancer patients

BACKGROUND: Lapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival rates. PURPOSE: To analyse the prescription profile used and the demographic and clinical characteristics of HER2-positive breast cancer (BC) pat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Hosp Pharm
Main Authors: Paredes, A Madrid, Herrera, S Guijarro, Casanova, N Martínez, Garre, M Cañadas
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Group 2018
Fag:
Section 5: Patient safety and quality assurance
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535278/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.422
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker